Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma
Table 1
Pretreatment and treatment characteristics.
Frequencies1 (%)
Definitive RT ()
Prostatectomy ()
value
Biopsy Gleason score
≤7
0
18 (37%)
<0.001
≥8
71 (100%)
31 (63%)
Clinical T stage
≤T2
63 (88.7%)
47 (96%)
0.162
T3
8 (11.3%)
2 (4%)
Clinical N stage
NX/N0
67 (94.4%)
49 (98%)
0.323
N1
4 (5.6%)
1 (2%)
Neoadjuvant and/or adjuvant ADT
Yes
68 (95.8%)
18 (36%)
<0.001
No
3 (4.2%)
32 (64%)
Preexisting diabetes
Yes
9 (12.7%)
10 (20%)
0.276
No
62 (87.3%)
40 (80%)
Preexisting coronary artery disease
Yes
15 (21.1%)
7 (14%)
0.317
No
56 (78.9%)
43 (86%)
Means2 (range)
Initial PSA:
9.58 (1.1–19.0)
11.52 (2.9–50.0)
0.350
Risk of LN involvement
13.02% (0–36.0%)
8.91% (0–36.0%)
0.006
Age at initial treatment
69.63 (50.44–83.61)
60.91 (42.43–75.34)
<0.001
Months of biochemical follow-up
73.74 (12.37–172.0)
60.03 (12.47–166.87)
0.045
Pearson test. Independent samples Mann-Whitney test. value < 0.05 is considered statistically significant. 3 patients clinically classified as T3 via MRI; 4 via DRE; and 1 via CT. 2 patients clinically classified as T3 via MRI. Based on updated Partin tables nomogram [6]. NX: lymph nodes not sampled; N0: lymph nodes negative for disease; N1: lymph nodes positive for disease; RT: radiotherapy; PSA: prostate specific antigen.
